Latest news with #IndustrialResearchAssistanceProgram
Cision Canada
10-06-2025
- Business
- Cision Canada
An AI solution from CIRRUS Intelligence showcased at the G7 Français
MIRABEL, QC, June 10, 2025 /CNW/ - CIRRUS Intelligence is proud to announce that its groundbreaking aviation safety solution, developed in collaboration with Nolinor Aviation, Mila, P3F, and the National Research Council of Canada (NRC), has been selected for presentation at the G7 Summit. It is the only project from Mila's ongoing research to have been developed in collaboration with an SME and selected for this international showcase. This project highlights the CIRRUS solution, designed to transform the management of safety events within the aviation industry's Safety Management System (SMS). Leveraging artificial intelligence, the technology reduces human involvement in incident analysis by up to 80%. Deployed in real-world operations at Nolinor Aviation, it has already cut some analysis processes from 40 hours to just 5, while minimizing human bias and standardizing data processing. The solution arrives at a pivotal moment, as Canadian and U.S. regulators move toward requiring formal SMS integration across all aviation operations. It also meets FAA regulations and aligns with the global shift toward embedding safety systemically within the aviation ecosystem. CIRRUS positions itself as a robust technological response to growing compliance and performance demands. "Being selected to represent Quebec innovation at the G7 Summit is an immense honor for our entire team. It's proof that a homegrown solution can have a real global impact. We strongly believe that applying artificial intelligence to concrete challenges—like aviation safety—can transform entire industries, and this project is a powerful example of that." – Olivier Richer, General Manager of CIRRUS Intelligence. The strength of the project lies in the alliance of four complementary players. P3F, the originator of the concept, led coordination and technology integration. Strategic partner Nolinor Aviation provided a real-world operational environment to test the solution. Mila, a global leader in artificial intelligence, ensured the innovation was built on rigorous scientific foundations. The NRC, through its Industrial Research Assistance Program (IRAP-NRC), which supports technological innovation in Canadian SMEs, also played a key role, contributing $500,000 in funding and actively supporting the project's development. CIRRUS Intelligence now leads the solution and is responsible for its commercialization, with the ambition of making it available across the aviation industry. This international recognition marks a major milestone for CIRRUS, as it rolls out its first large-scale project. Additional initiatives are already underway, aimed at exporting Quebec's expertise in applied artificial intelligence to other critical sectors. About CIRRUS Intelligence CIRRUS Intelligence is a Quebec-based company that specializes in consulting services and technological solutions for the aerospace sector. By combining expertise in safety, regulatory compliance, and digital innovation, CIRRUS develops intelligent tools that optimize processes and support better decision-making in aviation operations. With a performance-driven and data-centric approach, the company helps industry stakeholders navigate their technological transformation. To learn more about CIRRUS Intelligence and its services, visit For updates and news, follow @cirrusintelligence on Instagram.
Cision Canada
21-05-2025
- Health
- Cision Canada
Medirex announces funding support for innovative healthcare solution
TORONTO, May 21, 2025 /CNW/ - Medirex Systems Inc. is pleased to announce that it received advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a breakthrough project aimed at modernizing patient authentication in healthcare settings. This project builds on Medirex's trusted expertise in patient identification by introducing a new digital layer that transforms the traditional hospital wristband into a gateway for secure, verified access to personal health information. The solution, which is patent-pending, begins with in-person identity confirmation and the issuance of a wristband — enabling patients to initiate a secure connection from the hospital wristband to external systems without requiring hospital staff to manage or access data outside their responsibilities. At the core of this project is the Medirex Open API, a standards-based identity and authentication bridge that allows patients to authorize third-party applications — such as RPM systems — to access their health data from Electronic Health Record (EHR) systems like Epic and Oracle. Rather than sharing full medical records or giving hospital staff unnecessary access, the API enables patients to share only the identity and essential data needed to register and use external systems. This process begins with in-person verification and wristband issuance, and puts the patient fully in control — ensuring privacy, precision, and consent are at the center of every connection. The Medirex Patient Authentication API empowers patients to securely control access to their data across care settings — from hospital visits to at-home monitoring — while upholding the highest standards of privacy and security. By scanning their wristband and confirming their identity via SMS or email, patients can authorize access for themselves or for approved digital health tools such as RPM systems. This innovation directly addresses a key challenge in healthcare today: balancing data privacy with the needs of third-party care partners. Hospital staff do not always require access to the same data needed by external RPM providers or family caregivers. Medirex's solution creates a clear separation of access roles, ensuring that only the right stakeholders can see the right information — with patient consent at the center. "We're building on what hospitals already trust — the wristband — and adding a secure, patient-friendly way to unlock digital access," said Mark Caskenette, Managing Director at Medirex. "By enabling a secure, patient-led handoff from the hospital wristband to third-party tools, we ensure that care can extend beyond the hospital without compromising privacy or involving staff in unnecessary data access. Thanks to NRC IRAP's support, we're delivering a platform that protects patient privacy while expanding how and where care can be delivered." This project supports Medirex's mission to make healthcare more connected, transparent, and patient-centered. By combining physical identity verification with secure digital consent, Medirex is helping shape a healthcare ecosystem where patients are both empowered and protected. The project marks a significant milestone in Medirex's journey to becoming a leader in digital health solutions. By leveraging the support of NRC IRAP, Medirex is poised to set new standards in patient engagement and healthcare delivery through this API and its digital health platform, mySPOT. For more information about Medirex and patient authentication, please visit: About Medirex Systems Inc. Medirex Systems Inc. is a Canadian healthcare technology company specializing in patient identification and digital health innovation. With a strong focus on patient safety, secure data access, interoperability, and 360° patient engagement, Medirex develops technologies that help healthcare organizations deliver better, more responsive care. SOURCE Medirex Systems Inc.
Yahoo
21-05-2025
- Health
- Yahoo
Medirex announces funding support for innovative healthcare solution
TORONTO, May 21, 2025 /CNW/ - Medirex Systems Inc. is pleased to announce that it received advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a breakthrough project aimed at modernizing patient authentication in healthcare settings. This project builds on Medirex's trusted expertise in patient identification by introducing a new digital layer that transforms the traditional hospital wristband into a gateway for secure, verified access to personal health information. The solution, which is patent-pending, begins with in-person identity confirmation and the issuance of a wristband — enabling patients to initiate a secure connection from the hospital wristband to external systems without requiring hospital staff to manage or access data outside their responsibilities. At the core of this project is the Medirex Open API, a standards-based identity and authentication bridge that allows patients to authorize third-party applications — such as RPM systems — to access their health data from Electronic Health Record (EHR) systems like Epic and Oracle. Rather than sharing full medical records or giving hospital staff unnecessary access, the API enables patients to share only the identity and essential data needed to register and use external systems. This process begins with in-person verification and wristband issuance, and puts the patient fully in control — ensuring privacy, precision, and consent are at the center of every connection. The Medirex Patient Authentication API empowers patients to securely control access to their data across care settings — from hospital visits to at-home monitoring — while upholding the highest standards of privacy and security. By scanning their wristband and confirming their identity via SMS or email, patients can authorize access for themselves or for approved digital health tools such as RPM systems. This innovation directly addresses a key challenge in healthcare today: balancing data privacy with the needs of third-party care partners. Hospital staff do not always require access to the same data needed by external RPM providers or family caregivers. Medirex's solution creates a clear separation of access roles, ensuring that only the right stakeholders can see the right information — with patient consent at the center. "We're building on what hospitals already trust — the wristband — and adding a secure, patient-friendly way to unlock digital access," said Mark Caskenette, Managing Director at Medirex. "By enabling a secure, patient-led handoff from the hospital wristband to third-party tools, we ensure that care can extend beyond the hospital without compromising privacy or involving staff in unnecessary data access. Thanks to NRC IRAP's support, we're delivering a platform that protects patient privacy while expanding how and where care can be delivered." This project supports Medirex's mission to make healthcare more connected, transparent, and patient-centered. By combining physical identity verification with secure digital consent, Medirex is helping shape a healthcare ecosystem where patients are both empowered and protected. The project marks a significant milestone in Medirex's journey to becoming a leader in digital health solutions. By leveraging the support of NRC IRAP, Medirex is poised to set new standards in patient engagement and healthcare delivery through this API and its digital health platform, mySPOT. For more information about Medirex and patient authentication, please visit: About Medirex Systems Systems Inc. is a Canadian healthcare technology company specializing in patient identification and digital health innovation. With a strong focus on patient safety, secure data access, interoperability, and 360° patient engagement, Medirex develops technologies that help healthcare organizations deliver better, more responsive care. View original content: SOURCE Medirex Systems Inc. View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
ME Therapeutics Receives Support to Advance mRNA Therapeutic Candidates for Cancer and Inflammatory Disease
VANCOUVER, British Columbia, May 21, 2025--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed preclinical biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, today announced that its subsidiary, ME Therapeutics Inc., is receiving advisory services and up to $140,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The project will support the research and development of ME Therapeutic's mRNA therapeutic program targeting myeloid cell biology for the treatment of cancer and inflammatory disease. "We are pleased to receive this support from NRC IRAP, which builds on advisory services and funding received in past years, to allow us to further advance preclinical studies for our mRNA therapeutic candidates that target key myeloid cell pathways," said Salim Dhanji, CEO of ME Therapeutics. "Our team at ME Therapeutics passionately believes myeloid cell-derived mRNA therapies represent the next wave of treatments for patients with cancer and inflammatory disease who today have limited treatment options, and we are committed to bringing these potential new approaches to the clinic as soon as possible." ME Therapeutics's proprietary mRNA sequences have been engineered to encode for proteins that can modify the immune response in vivo in a targeted manner. Their lead mRNA therapeutic candidate is specifically designed to modulate immune cells in the tumour microenvironment and stimulate an anti-cancer immune response. Preclinical testing has already demonstrated encouraging anti-cancer activity in a mouse model of colorectal cancer. In addition, ME Therapeutics is exploring design modifications of its mRNA candidates to modulate mRNA expression in a tissue-specific manner for increased efficacy and safety. About ME Therapeutics Myeloid Enhancement (ME) Therapeutics is a publicly listed, preclinical stage biotechnology company based in Vancouver involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. Our focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells to enhance anti-cancer immunity. For more information, visit Neither the Canadian Securities Exchange nor any Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward-Looking Statements This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements in this news release include, but are not limited to, statements regarding the Company's collaborations, research plans, the timing for completion of studies and the receipt of results, the intended outcomes of the research, the intended benefits and applications of the Company's technology, and the Company's plans for development of its business. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company, that the results of the testing are not favorable, that future research does not support continued development, that regulatory approvals are not obtained or maintained, that challenges related to mRNA technology development, including delivery, stability, or efficacy issues cannot be overcome, that the Company relies on third-party collaborators and vendors for certain aspects of the research, that the research will not be completed within the expected timeline, that the Company is unable to obtain intellectual property protection for the results, that the Company may require additional funding to advance its research and develop its business, and that the Company's business may not develop as set out in this news release. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ from forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. View source version on Contacts Media Claire PiechMagnetic Communicationsclaire@ +1-604-698-6637
Business Wire
21-05-2025
- Business
- Business Wire
ME Therapeutics Receives Support to Advance mRNA Therapeutic Candidates for Cancer and Inflammatory Disease
VANCOUVER, British Columbia--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. ('ME Therapeutics' or the 'Company') (CSE: METX) (FSE: Q9T), a publicly listed preclinical biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, today announced that its subsidiary, ME Therapeutics Inc., is receiving advisory services and up to $140,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The project will support the research and development of ME Therapeutic's mRNA therapeutic program targeting myeloid cell biology for the treatment of cancer and inflammatory disease. 'We are pleased to receive this support from NRC IRAP, which builds on advisory services and funding received in past years, to allow us to further advance preclinical studies for our mRNA therapeutic candidates that target key myeloid cell pathways,' said Salim Dhanji, CEO of ME Therapeutics. 'Our team at ME Therapeutics passionately believes myeloid cell-derived mRNA therapies represent the next wave of treatments for patients with cancer and inflammatory disease who today have limited treatment options, and we are committed to bringing these potential new approaches to the clinic as soon as possible.' ME Therapeutics's proprietary mRNA sequences have been engineered to encode for proteins that can modify the immune response in vivo in a targeted manner. Their lead mRNA therapeutic candidate is specifically designed to modulate immune cells in the tumour microenvironment and stimulate an anti-cancer immune response. Preclinical testing has already demonstrated encouraging anti-cancer activity in a mouse model of colorectal cancer. In addition, ME Therapeutics is exploring design modifications of its mRNA candidates to modulate mRNA expression in a tissue-specific manner for increased efficacy and safety. About ME Therapeutics Myeloid Enhancement (ME) Therapeutics is a publicly listed, preclinical stage biotechnology company based in Vancouver involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. Our focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells to enhance anti-cancer immunity. For more information, visit Neither the Canadian Securities Exchange nor any Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward-Looking Statements This news release includes certain 'forward-looking statements' under applicable Canadian securities legislation. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements in this news release include, but are not limited to, statements regarding the Company's collaborations, research plans, the timing for completion of studies and the receipt of results, the intended outcomes of the research, the intended benefits and applications of the Company's technology, and the Company's plans for development of its business. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company, that the results of the testing are not favorable, that future research does not support continued development, that regulatory approvals are not obtained or maintained, that challenges related to mRNA technology development, including delivery, stability, or efficacy issues cannot be overcome, that the Company relies on third-party collaborators and vendors for certain aspects of the research, that the research will not be completed within the expected timeline, that the Company is unable to obtain intellectual property protection for the results, that the Company may require additional funding to advance its research and develop its business, and that the Company's business may not develop as set out in this news release. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ from forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
